Evidence map›Paper›PMID 38271655›Full record

ArticleJCO precision oncology2024

Characteristics and Survival Outcomes of Patients With Metastatic

Allan Hackshaw, Otto Fajardo, Urania Dafni, Hans Gelderblom, Pilar Garrido, Salvatore Siena, Matthew H Taylor, Walter Bordogna, Christos Nikolaidis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Allan HackshawCancer Research UK, University College London Cancer Trials Centre, London, United Kingdom.
Otto FajardoF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0002-3363-9287
Urania DafniFrontier Science Foundation Hellas, and School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0003-4367-4497
Hans GelderblomDepartment of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0001-9270-8636
Pilar GarridoDepartment of Medical Oncology, Ramón y Cajal University Hospital, IRYCIS (Instituto Ramón y Cajal Investigación Sanitaria), Madrid, Spain.
Salvatore SienaDepartment of Oncology and Hemato-Oncology, Universitá degli Studi di Milano, and Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.ORCID 0000-0002-2681-2846
Matthew H TaylorEarle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR.ORCID 0000-0003-2409-9001
Walter BordognaF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Christos NikolaidisF. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0001-7119-2562

Funding

Cancer Research UK 25349
6 · The paper itself

Abstract

purpose

methodsData for RET TKI-naïve patients with metastatic solid tumors (excluding NSCLC) who had ≥one Foundation Medicine comprehensive genomic profiling test (January 1, 2011-March 31, 2022) were obtained from a deidentified nationwide (US-based) clinicogenomic database. The primary objective of this study was to compare the overall survival (OS) of patients with

resultsThe study population included 26 patients in the

conclusionThese data suggest that

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansPrognosisProto-Oncogene Proteins c-retStandard of CareProto-Oncogene Proteins c-retRET protein, human

Identifiers

PMID38271655
PMCPMC10830092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.